Eiber, Matthias

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

Eiber, M., Herrmann, K., Calais, J., Hadaschik, B., Giesel, F. L., Hartenbach, M., Hope, T., Reiter, R., Maurer, T., Weber, W. A., et al. (2018) · Journal of Nuclear Medicine

Prostate Cancer Diagnosis and TreatmentMedical Imaging Techniques and Applications

Cited by 626

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

Gafita, A., Calais, J., Grogan, T. R., Hadaschik, B., Wang, H., Weber, M., Sandhu, S., Kratochwil, C., Esfandiari, R., Tauber, R., et al. (2021) · The Lancet Oncology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 271

Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer

Fendler, W. P., Weber, M., Iravani, A., Hofman, M. S., Calais, J., Czernin, J., Ilhan, H., Saad, F., Small, E. J., Smith, M. R., et al. (2019) · Clinical Cancer Research

Prostate Cancer Diagnosis and TreatmentProstate Cancer Treatment and Research

Cited by 266

A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging

Kaissis, G., Ziegelmayer, S., Lohöfer, F., Algül, H., Eiber, M., Weichert, W., Schmid, R., Friess, H., Rummeny, E., Ankerst, D., et al. (2019) · European Radiology Experimental

Radiomics and Machine Learning in Medical ImagingMRI in cancer diagnosis

Cited by 79

False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial

Fendler, W. P., Calais, J., Eiber, M., Simko, J. P., Kurhanewicz, J., Santos, R. D., Feng, F. Y., Reiter, R. E., Rettig, M. B., Nickols, N. G., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging

Prostate Cancer Diagnosis and TreatmentRadiopharmaceutical Chemistry and Applications

Cited by 56

The Impact of PSMA PET–Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy

Karimzadeh, A., Heck, M., Tauber, R., Solaris, E., Nekolla, S., Knorr, K., Haller, B., D’Alessandria, C., Weber, W. A., Eiber, M., et al. (2023) · Journal of Nuclear Medicine

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 19

Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.

Krause, B. J., Chi, K. N., Sartor, A. O., Fizazi, K., Morris, M. J., De Bono, J. S., Tagawa, S. T., Herrmann, K., Kurth, J., Eiber, M., et al. (2023) · Journal of Clinical Oncology

Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications

Cited by 11